MicroRNAs and adipocytokines: Promising biomarkers for pharmacological targets in diabetes mellitus and its complications

• Published in: Biomedicine & pharmacotherapy Vol. 93; pp. 1326 - 1336
• Main Authors: Ashoori, Mohamad Reza, Rahmati-Yamchi, Mohammad, Ostadrahimi, Alireza, Fekri Aval, Sedigheh, Zarghami, Nosratollah
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-09-2017
• Subjects: Adipocytokine; Adipokines - metabolism; Biomarkers - metabolism; Blood Glucose - genetics; Diabetes Mellitus, Type 2 - genetics; Gene Expression - genetics; Humans; Insulin - genetics; MicroRNA; MicroRNAs - genetics; Obesity; Pharmacological target; Prediabetic State - genetics; Adipocytokine; Obesity; MicroRNA; Pharmacological target
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2017.07.059

Nowadays, diabetes mellitus (DM) along with its complications is considered as a fundamental problem in both developing and industrial countries, and is causing millions of people to suffer worldwide. Currently, diabetes mellitus is diagnosed traditionally or classically in the world by measuring fasting blood glucose and conducting oral glucose tolerance test. New alternatives are required for the treatment of diabetes mellitus, especially type 2 diabetes mellitus (T2DM), at its early levels due to the ineffective control of its development in patients. In recent years, by further identifying of molecular agents such as microRNAs (miRNAs), studies have focused on miRNAs in diabetes as well as in other diseases. These small non-coding RNA molecules have a significant role in the regulation of insulin gene expression and also, obesity problems. White adipose tissue, as an important tissue in obese subjects, is directly related to type 2 diabetes and its complications via synthesis of adipokines. Prevention and treatment of obesity should be noted since childhood. Our aim in this review is to briefly provide a new glance at types of potential biomarkers, which can be used as pharmacological targets for prevention and treatment of prediabetic subjects, and patients with T2DM.